Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in human Phase 1 study investigating its lead candidate BTX-1188, an oral, dual target protein degrader specifically engineered to degrade GSPT1 and IKZF1/3, in patients with advanced hematologic and solid tumor malignancies.

“BTX-1188 has demonstrated rapid, deep and durable degradation of both GSPT1 and IKZF1/3 at low nanomolar concentrations in preclinical models, and we are delighted to make this exciting advancement into the clinic,” said Zung Thai, M.D., Ph.D., Chief Medical Officer of BioTheryX. “We are grateful to our clinical trial site partners for initiating this study in these challenging times and thank them for their commitment to investigating potential new therapeutic options for people facing difficult-to-treat cancers.”

The Phase 1 clinical trial is a multicenter, open label, non-randomized, sequential dose escalation study to assess the safety, pharmacokinetics and preliminary efficacy of BTX-1188 in patients with acute myeloid leukemia, advanced lymphoid and solid tumors who have failed standard therapy. The primary objective of the Phase 1 study is to determine a recommended Phase 2 dose, which will then be carried forward into expansion cohorts where the safety and efficacy of BTX-1188 will be evaluated in both hematologic and solid tumor malignancies. More information can be found on clinicaltrials.gov (NCT05144334).

“BTX-1188 is one of many potential best-in-class protein degrader candidates our team has designed and developed leveraging our distinctive PRODEGY targeted protein degradation platform to provide new treatment approaches for people living with cancer and other diseases,” said Philippe Drouet, President and Chief Executive Officer of BioTheryX. “With our clinical trial site partners, we are working as expeditiously as possible to study BTX-1188 and validate the potential of our platform.”

About BTX-1188
BTX-1188 is the first orally bioavailable, rationally designed dual target protein degrader, engineered to specifically degrade validated oncology targets GSPT1 and IKZF1/3. By degrading GSPT1 and IKZF1/3, BTX-1188’s profile is expected to be differentiated from protein degraders that exclusively target GSPT1. Preclinical data for BTX-1188 has shown rapid, deep and durable degradation of these targets at low nanomolar concentrations. Acute myeloid leukemia (AML) xenograft experiments have also shown significant decreases in tumor volume and increased survival compared to controls and other degraders of GSPT1. BioTheryX believes BTX-1188 has broad potential applicability in both hematologic and solid tumor malignancies and is currently studying the molecule in both settings as part of a Phase 1 clinical study.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine